Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Etofenamate→

Etofenamate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
30544-47-9
Molecular formula
C18H18F3NO4
Molecular weight
369.33 g/mol
Drug class
Topical non-steroidal anti-inflammatory drug (NSAID)fenamate derivative
Mechanism of action
A lipophilic prodrug that penetrates skin and is metabolised to flufenamic acid and related active metabolites, inhibiting cyclo-oxygenase/prostaglandin synthesis and reducing local inflammation and pain.
Indications / reported uses
  • Topical symptomatic treatment of pain and inflammation associated with acute blunt injuries such as sprains, strains and contusions, and local soft-tissue rheumatic conditions, depending on the authorised formulation

Sources: UK SmPC search — Etofenamate topical preparations · PubMed pharmacology search — Etofenamate and flufenamic acid · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Topical non-steroidal anti-inflammatory drug (NSAID); fenamate derivative

Mechanism of action

A lipophilic prodrug that penetrates skin and is metabolised to flufenamic acid and related active metabolites, inhibiting cyclo-oxygenase/prostaglandin synthesis and reducing local inflammation and pain.

General use cases

  • Topical symptomatic treatment of pain and inflammation associated with acute blunt injuries such as sprains, strains and contusions, and local soft-tissue rheumatic conditions, depending on the authorised formulation

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Etofenamate Environmental Risk Assessment (ERA) (the Etofenamate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.